Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The Journal of Clinical Endocrinology & Metabolism
Stougaard EB, Rossing P, Vistisen D et al (2023) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes
report any sudden vision changes Hypoglycaemia risk : Particularly when used with sulfonylureas or insulin
In the UK, NICE guidance (NG28) recommends considering GLP-1 receptor agonists for patients with type 2 diabetes according to specific criteria, typically when treatment with metformin and other oral medications has not achieved adequate glycaemic control
Correct subcutaneous injection technique involves pinching the skin to create a fold, inserting the needle at a 45-degree angle into fatty tissue, aspirating briefly to confirm youre not in a blood vessel, and injecting slowly over 510 seconds
SURMOUNT-1 reported up to 22.5% mean body-weight reduction at the highest studied dose over 72 weeks
US$ 25.75
US$ 28.92
US$ 21.40
US$ 25.81
